Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market.
Company name: Aptar Pharma
Address: 36-38 rue de la Princesse, 78430 Louveciennes, France
Telephone: +33 1 39 17 20 20
Fax: +33 1 39 58 12 98
E-mail: guillaume.le_brun@aptar.com
Website: www.aptar.com
No. of employees: 2 280
Date founded: 1947
Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.
Aptar Pharma is market driven with a strong focus on specific therapeutic areas such as as allergic rhinitis, asthma, COPD, pain management, hormone therapies, mucosal vaccines as well as cough & cold ailments.
The Aptar Pharma Prescription Division specializes in novel drug delivery solutions - i.e. pMDIs, DPIs, Spray Pumps and UnitDoses - specific to physician-prescribed medicines while the Consumer Health Care Division offers dispensing solutions adapted to over-the-counter medications.
Our manufacturing facilities are located in Buenos Aires (Argentina), Congers (NY, U.S.A.), Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France) and Suzhou (near Shanghai, R.O.C.).
Approximately 6% of Aptar Pharma’s annual turnover is dedicated to research, development and industrialization of novel products. Our R&D and Marketing staff work closely together in a global market-focused team of 200 people dedicated to satisfying customer needs.
Aptar Pharma R&D centres of excellence are located in Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France).
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.